ClinicalTrials.gg
RecruitingNCT07693049CPHIT-HFpEFUpdated Oct 21, 2026

Cardiopulmonary Exercise Testing-based High-intensity Interval Training For Improving Heart Failure With Preserved Ejection Fraction

An interventional study of High-intensity interval training in HFpEF - Heart Failure With Preserved Ejection Fraction, sponsored by Peking University Third Hospital. Recruiting at 13 sites in China. Open to participants aged 35 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Peking University Third Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 21, 2026Now RecruitingPrimary outcomes revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
35 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 132 studies in Motor Activity with a site in China — 41 open to participants now, 49 under way, 1 of them phase 3. Motor Activity · China.

Planned enrollment
38th of 113
192 · median 113
Started
2026
with 21 others
No phase
105 of 132
29 open now
Primary completion
2027-07
later than 41 of 48 live
Registered
114th of 132
by date
Lead sponsor
3 of 132
Peking University Third Hospital

Among the 132 studies in Motor Activity with a site in China, this one is the 38th largest by planned enrollment of the 113 interventional ones that give a count, is one of 22 that started in 2026, is one of 105 with no phase, reaches primary completion later than 41 of the 48 other live ones, and was the 114th registered.

Motor Activity

9,827 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.

Browse Motor Activity studies →

Open to participants now

41 of the 132 studies in Motor Activity with a site in China are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,207 Motor Activity studies recruiting now, 524 (43%) set no upper age limit and 538 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.

This study: 35 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Motor Activity with a site in China, or all of them as a file.
02

Study summary

Cardiovascular-Kidney-Metabolic (CKM) Syndrome is a continuous clinical disease spectrum integrating cardiovascular, renal, and metabolic disorders. Heart failure with preserved ejection fraction (HFpEF) is considered Stage 4 of CKM syndrome, characterized primarily by impairment of cardiac structure and function. Numerous studies have confirmed that exercise intervention is effective in improving metabolic profiles and inflammatory status in Stages 0-3 of CKM syndrome (e.g., obesity, metabolic syndrome, hypertension, and diabetes), and significantly improves clinical outcomes. However, for Stage 4 CKM syndrome, especially in patients with HFpEF, conventional exercise prescription faces significant challenges in balancing safety and efficacy. Moreover, traditional "one-size-fits-all" exercise rehabilitation strategies have failed to significantly improve clinical outcomes due to the lack of individualized precision approaches.

To address this gap, this study proposes to adopt a multicenter, randomized, controlled design, enrolling patients with HFpEF at Stage 4 of CKM syndrome and randomly assigning them to either a personalized high-intensity interval training (HIIT) intervention group or a standard care control group. The **primary endpoint** of this study is the change in peak oxygen consumption (peak VO₂) from baseline after 24 weeks of intervention. In addition, a series of **secondary endpoints** have been established for comprehensive evaluation, including inflammatory biomarkers, cardiac structure and function, quality of life, and composite clinical events. These endpoints aim to comprehensively assess the intervention effects from the perspectives of cardiopulmonary function, metabolism and inflammation, quality of life, and clinical outcomes, as well as to explore the underlying mechanisms.

This study is expected to validate the beneficial effects of personalized exercise on peak VO₂ and various secondary endpoints in patients with Stage 4 CKM syndrome. It will not only provide high-level evidence-based support for exercise therapy in HFpEF but also deepen the understanding of the role of exercise intervention in the full-course management of CKM syndrome, offering key scientific support for the development of precision prevention and treatment strategies across all stages.

03

Conditions studied

  • HFpEF - Heart Failure With Preserved Ejection Fraction

Browse trials for

Keywords

  • HFpEF
  • CPET
  • HIIT
  • Peak VO2
  • Exercise
04

Who can participate

Ages eligible
35 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women aged 35-70 years;
  2. Physical inactivity / sedentary lifestyle defined as:

    Sedentary behavior: average daily sitting time > 6 hours over the past 6 months; AND/OR Insufficient physical activity: average weekly moderate-intensity physical activity \< 150 minutes or vigorous-intensity physical activity \< 75 minutes as assessed by the International Physical Activity Questionnaire (IPAQ);

  3. Patients with HFpEF at Stage 4 of CKM syndrome who have been clinically stable within the past month ( [NYHA] functional class II-III);
  4. Willingness to improve health status through appropriate exercise.

Exclusion criteria

Exclusion Criteria:

  1. Presence of to cardiopulmonary exercise testing (CPET);
  2. Positive findings on the exercise (ECG) during CPET;
  3. Diagnosis of psychiatric disorders;
  4. Presence of movement disorders or lower extremity exercise-related injuries within the past 6 months;
  5. Women who are pregnant, breastfeeding, or planning to become pregnant in the near future;
  6. Other conditions deemed unsuitable for participation in this study by the investigators;
  7. Refusal to sign the form.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
192 participants (estimated)

Study arms

  • Experimental
    HIIT intervention group

    Subjects in the intervention group will undergo a 24-week personalized high-intensity interval training (HIIT) program, four times per week, with the exercise protocol tailored based on cardiopulmonary exercise testing (CPET). In addition, they will receive guideline-directed healthy lifestyle recommendations and optimal medical therapy (GDMT)

    Behavioral: High-intensity interval training

  • No intervention
    Standard care control group

    Control group subjects will receive guideline-directed optimal medical therapy (GDMT) , identical to that provided to the intervention group. In addition, they will receive a single, standardized health education session focused on HFpEF and obesity management, covering general recommendations regarding diet, weight management, and regular physical activity. No structured or supervised exercise prescription or program will be offered to the control group.

Interventions

  • BehavioralHigh-intensity interval training

    Subjects in the intervention group will receive a personalized high-intensity interval training (HIIT) protocol based on cardiopulmonary exercise testing (CPET) and will undergo a 24-week HIIT intervention, four times per week.The exercise protocol consisted of a 5-minute warm-up at 30-40 watts, followed by 8 cycles of high-intensity exercise performed at 80-90% of peak VO₂ for 30 seconds, each interspersed with a 60-second active recovery period of low-intensity exercise at 50-60% of peak VO₂ , and concluded with a 5-minute cool-down at 30-40 watts.

06

What researchers measure

Primary outcomes

  1. Peak VO2

    Peak VO2 (mL/kg/min) will be measured using symptom-limited incremental cardiopulmonary exercise testing performed on an electronically braked cycle ergometer

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

Secondary outcomes

  1. Blood specimen

    Lab tests include cytokines

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  2. Blood specimen

    Lab tests include high-sensitivity C-reactive protein (hs-CRP)

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  3. Blood specimen

    Lab tests include adipokines

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  4. Blood specimen

    Lab tests include N-terminal pro-B-type natriuretic peptide (NT-proBNP)

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  5. Blood specimen

    Lab tests include cardiac troponin

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  6. Kansas City Cardiomyopathy Questionnaire (KCCQ)

    The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered, disease-specific instrument that assesses physical limitations, symptoms (frequency, severity, and change), self-efficacy, social function, and quality of life in patients with heart failure. It has demonstrated high reliability and validity. Scores are transformed to a range of 0 to 100, with higher scores reflecting better health-related quality of life.

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  7. The New York Heart Association (NYHA) Functional Classification

    The New York Heart Association (NYHA) Functional Classification is a commonly used tool by clinicians to quantify the severity of symptoms and physical activity limitations in patients with heart failure. The classification places patients into one of four categories: Class I (no limitation of physical activity), Class II (slight limitation, ordinary activity causes symptoms), Class III (marked limitation, less than ordinary activity causes symptoms), and Class IV (unable to carry on any physical activity without discomfort, symptoms may be present at rest).

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  8. Montreal Cognitive Assessment (MoCA)

    The Montreal Cognitive Assessment (MoCA) is a standardized 30-point screening tool used to detect cognitive impairment. It assesses multiple cognitive domains including visuospatial/executive function, naming, memory, attention, language, abstraction, delayed recall, and orientation. The test takes approximately 10 minutes to administer. Scores range from 0 to 30, with higher scores reflecting better cognitive function. A score of 26 or above is generally considered normal; 18-25 indicates mild cognitive impairment; 10-17 indicates moderate cognitive impairment; and below 10 indicates severe cognitive impairment. One point is added to the raw score for individuals with 12 or fewer years of education.

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  9. Hospital Anxiety and Depression Scale (HADS)

    The Hospital Anxiety and Depression Scale (HADS) is a 14-item, self-administered screening tool designed to assess symptoms of anxiety and depression. It comprises two independent subscales: anxiety (HADS-A) and depression (HADS-D), each containing 7 items. Each item is scored from 0 to 3, yielding a subscale total score ranging from 0 to 21, with higher scores indicating greater symptom severity. Based on established cutoffs, scores of 0-7 are considered normal, 8-10 indicate borderline abnormal (mild), and 11-21 indicate abnormal (moderate to severe).

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  10. Pittsburgh Sleep Quality Index (PSQI)

    The Pittsburgh Sleep Quality Index (PSQI) is a 19-item, self-rated questionnaire that assesses sleep quality over a 1-month time interval. It comprises seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Each component is scored from 0 to 3, and the sum of these seven components yields a global PSQI score ranging from 0 to 21, with higher scores indicating poorer sleep quality.

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  11. International Physical Activity Questionnaire (IPAQ)

    The International Physical Activity Questionnaire (IPAQ) Long Form is a 27-item, self-administered questionnaire that assesses physical activity over the past 7 days across five life domains: work-related activity, transportation-related activity, domestic and gardening activity, leisure-time activity, and sitting time. Metabolic equivalent (MET) values assigned are: walking = 3.3 METs, moderate-intensity activity = 4.0 METs, and vigorous-intensity activity = 8.0 METs. Activity volume for each domain is calculated as MET-minutes per week (MET-min/week) using the formula: MET value × days per week × minutes per day. Total physical activity is derived by summing MET-min/week across all domains. Based on total MET-min/week, participants are classified into three levels: low (\< 600 MET-min/week), moderate (600-3000 MET-min/week), and high (≥ 3000 MET-min/week)

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  12. Peak O₂ pulse

    Peak O₂ pulse will be assessed by cardiopulmonary exercise testing (CPET) .

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  13. Anaerobic Threshold (AT)

    Anaerobic Threshold (AT) will be assessed by cardiopulmonary exercise testing (CPET) .

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  14. VE/VCO₂ slope

    VE/VCO₂ slope will be assessed by cardiopulmonary exercise testing (CPET) . Ventilation (VE) and carbon dioxide output (VCO₂) will be measured breath-by-breath throughout the test. The VE/VCO₂ slope will be calculated by linear regression analysis of VE versus VCO₂ using data from the beginning of exercise up to the respiratory compensation point (RCP).

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  15. left atrial volume index (LAVI) assessed by echocardiography

    Left atrial volume index (LAVI) will be assessed using echocardiography. LAVI is calculated as left atrial volume indexed to body surface area (BSA), and will be reported in mL/m².

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  16. left atrial volume index (LAVI) assessed by cardiac magnetic resonance(CMR)

    Left atrial volume index (LAVI) will be measured by cardiac magnetic resonance(CMR). LAVI is calculated as left atrial volume indexed to body surface area (BSA) and reported in mL/m².

    Time frame: Baseline(week 0),End of study(week 24 )

  17. Left ventricular mass index (LVMI) assessed by echocardiography

    Left ventricular mass index (LVMI) will be measured by echocardiography. LVMI is derived by indexing LVM to body surface area (BSA) and reported in g/m².

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  18. Left ventricular mass index (LVMI) assessed by cardiac magnetic resonance(CMR)

    Left ventricular mass index (LVMI) will be measured by cardiac magnetic resonance(CMR). LVMI is derived by indexing LVM to body surface area (BSA) and reported in g/m².

    Time frame: Baseline(week 0),End of study(week 24)

  19. left atrial volume (LAV)

    Left atrial volume (LAV) will be assessed using echocardiography , and will be reported in mL.

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  20. left atrial area (LAA)

    Left atrial area (LAA) will be measured by echocardiography . Left atrial area index (LAAI) will be calculated as LAA max divided by body surface area (BSA) and reported in cm²/m².

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  21. left atrial diameter (LAD)

    Left atrial diameter (LAD) will be measured by echocardiography and reported in mm.

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  22. Diastolic function index (E/e' ratio)

    Diastolic function index (E/e' ratio) will be measured by echocardiography. The E/e' ratio is a noninvasive surrogate marker for estimating left ventricular filling pressure and is central to the grading of diastolic dysfunction.

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  23. Global longitudinal strain (GLS)

    Global longitudinal strain (GLS) will be measured by echocardiography and reported in %. GLS is expressed as a negative value, with more negative values indicating better left ventricular systolic function.

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  24. Left ventricular myocardial work (MW)

    Left ventricular myocardial work (MW) will be assessed by echocardiography and reported in mmHg%.

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  25. Left atrial strain (LAS)

    Left atrial strain (LAS) will be measured by echocardiography and reported in %.

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  26. Epicardial adipose tissue volume (EATV)

    Epicardial adipose tissue volume (EATV) will be quantified using cardiac magnetic resonance (CMR) and reported in mL.

    Time frame: Baseline(week 0),End of study(week 24 )

  27. Pericardial adipose tissue volume

    Pericardial adipose tissue volume will be quantified using cardiac magnetic resonance (CMR) and reported in mL

    Time frame: Baseline(week 0),End of study(week 24 )

  28. Liver fat content (LFC)

    Liver fat content (LFC) will be quantified using magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) and expressed as a percentage (%)

    Time frame: Baseline(week 0),End of study(week 24 )

  29. Liver Stiffness Measurement(LSM)assessed by magnetic resonance elastography (MRE)

    Liver stiffness measurement (LSM) will be assessed by magnetic resonance elastography (MRE) and reported in kilopascals (kPa), with higher values indicating more severe liver fibrosis

    Time frame: Baseline(week 0),End of study(week 24 )

  30. Liver Stiffness Measurement(LSM)assessed by FibroTouch transient elastography

    Liver stiffness measurement (LSM) will be assessed using the FibroTouch transient elastography system and reported in kilopascals (kPa).

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  31. Visceral adipose tissue area (VATA)

    Visceral adipose tissue area (VATA) will be measured using non-contrast chest CT and reported in cm²

    Time frame: Baseline(week 0),End of study(week 24 )

  32. BMI

    Weight (kg) is measured with digital weighing scale. Height (cm) is measured with a portable stadiometer. BMI is calculated as weight in kilograms divided by the square of height in meters

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  33. Waist-to-height ratio (WHtR)

    Waist-to-height ratio (WHtR) will be calculated using standard anthropometric measurements. Waist circumference will be measured at the midpoint between the lower costal margin and the iliac crest at the mid-axillary line at the end of expiration. WHtR is calculated as waist circumference divided by height.

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  34. Waist-to-hip ratio (WHR)

    Waist-to-hip ratio (WHR) will be calculated using standard anthropometric measurements. Waist circumference will be measured at the midpoint between the lower costal margin and the iliac crest at the mid-axillary line at the end of expiration; hip circumference will be measured at the maximal gluteal protuberance. WHR as waist circumference divided by hip circumference.

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

  35. All-Cause Death

    All-cause death is defined as death from any cause occurring from baseline to the end of follow-up. Death information will be ascertained through regular follow-up, medical record review, and family reports. For participants lost to follow-up, vital status will be confirmed by cross-referencing with the local population death registry. This study will report the incidence of all-cause death from randomization to the end of study.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24

  36. Heart failure rehospitalization

    Heart failure rehospitalization is defined as an unplanned hospitalization (≥24 hours) due to decompensated heart failure, requiring at least one of the following intravenous therapies during the hospital stay: (1) intravenous diuretics; (2) intravenous vasodilators; or (3) intravenous inotropic agents. This study will report the incidence of heart failure rehospitalization from baseline to the end of the study.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24

  37. Exercise intervention-related adverse events

    Exercise intervention-related adverse events are defined as any adverse medical events occurring during participation in the exercise intervention protocol or within post-exercise, judged by the investigator to have a possible, probable, or definite causal relationship with the study exercise intervention. These include, but are not limited to, exercise-induced arrhythmias, angina, hypotensive/hypertensive crises, and musculoskeletal injuries requiring medical intervention. The overall incidence of exercise-related adverse events will be reported from baseline to the end of the study.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24

  38. Clinical deterioration

    Clinical deterioration is defined as any of the following events due to worsening heart failure that do not meet hospitalization criteria: (1) unscheduled clinic visit for worsening HF symptoms (dyspnea, edema, fatigue) requiring therapy intensification; (2) emergency department observation (\<24 hours) for decompensated HF; (3) outpatient/day-care intravenous diuretics or vasodilators; or (4) significant upward titration of oral diuretics (e.g., dose doubling or new agent), confirmed by the investigator. Events progressing to hospitalization will be captured under "HF rehospitalization" and excluded here. Incidence will be reported as proportion of participants from baseline to the end of the study.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24

  39. Fecal specimens

    Fecal specimens will be collected at baseline and Week 24 for gut microbiome profiling.

    Time frame: Baseline(week 0),Mid-term(week 12),End of study(week 24 )

07

Study locations

1 of 13 sites recruiting
  • Beijing Chao-Yang Hospital, Capital Medical University
    Beijing, China
    Not yet recruiting
    • Yuanhua Yang · Principal investigator
  • Beijing Hospital
    Beijing, China
    Not yet recruiting
    • Qian Zhang · Principal investigator
  • Beijing Xiaotangshan Hospital
    Beijing, China
    Not yet recruiting
    • Rong Guo · Principal investigator
  • Beijing Zhongguancun Hospital
    Beijing, China
    Not yet recruiting
    • Chaoyi Zhang · Principal investigator
  • Community Health Station of the Party School of the Central Committee of C.P.C
    Beijing, China
    Not yet recruiting
    • Wei Zhao · Principal investigator
  • Jimenli Community Health Service Center
    Beijing, China
    Not yet recruiting
    • Qiue Zhang · Principal investigator
  • Peking University First Hospital
    Beijing, China
    Not yet recruiting
    • Jianping Li · Principal investigator
  • Peking University People's Hospital
    Beijing, China
    Not yet recruiting
    • Jian Liu · Principal investigator
  • Peking University Third Hospital
    Beijing, China
    Recruiting
  • Xueyuanlu Community Health Service Center
    Beijing, China
    Not yet recruiting
    • Hongyun Chi · Principal investigator
  • Qingdao Municipal Hospital
    Qingdao, China
    Not yet recruiting
    • Yibing Shao · Principal investigator
  • Shanghai East Hospital
    Shanghai, China
    Not yet recruiting
    • Ying Li · Principal investigator
  • Wuhan Asia Heart Hospital
    Wuhan, China
    Not yet recruiting
    • Yin Li · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jul 2027, 11 months after the start.

Of 5,176 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 11 months is below that.

Counting every sponsor, half of 5,236 studies reached it within 17 months; a quarter within 7 and three quarters within 36.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Aug 2026, on Sep 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2026
First posted
Jul 9, 2026
StartActual
Aug 10, 2026was Jul 2026
Primary completionEst.
Jul 2027
CompletionEst.
Apr 30, 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 30, 2026
Sites
1 site added. 12 sites changed recruiting status (11 now not yet recruiting, 1 now recruiting)
Show 12 sites
  • Beijing Chao-Yang Hospital, Capital Medical University · Beijing, Chinano status→Not yet recruiting
  • Beijing Hospital · Beijing, Chinano status→Not yet recruiting
  • Beijing Xiaotangshan Hospital · Beijing, Chinano status→Not yet recruiting
  • Beijing Zhongguancun Hospital · Beijing, Chinano status→Not yet recruiting
  • Community Health Station of the Party School of the Central Committee of C.P.C · Beijing, Chinano status→Not yet recruiting
  • Jimenli Community Health Service Center · Beijing, Chinano status→Not yet recruiting
  • Peking University First Hospital · Beijing, Chinano status→Not yet recruiting
  • Peking University People's Hospital · Beijing, Chinano status→Not yet recruiting
  • Peking University Third Hospital · Beijing, Chinano status→Recruiting
  • Xueyuanlu Community Health Service Center · Beijing, Chinano status→Not yet recruiting
  • Shanghai East Hospital · Shanghai, Chinano status→Not yet recruiting
  • Wuhan Asia Heart Hospital · Wuhan, Chinano status→Not yet recruiting
Show site
  • Qingdao Municipal Hospital · Qingdao, China
Sep 30, 2026
Start date
Jul 2026→Aug 10, 2026 (actual)
Sep 30, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionPeak VO2: how it is measured was reworded
Oct 21, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Beijing Hospital · Beijing, ChinaContact person changed (no phone or email listed)
Sep 30, 2026
Show all 2 updates
  1. Oct 21, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionPeak VO2: how it is measured was reworded
    + 1 other change: verification date
  2. Sep 30, 2026
    Not yet recruiting→Recruiting
    1 site added. 12 sites changed recruiting status (11 now not yet recruiting, 1 now recruiting)
    Show 12 sites
    • Beijing Chao-Yang Hospital, Capital Medical University · Beijing, Chinano status→Not yet recruiting
    • Beijing Hospital · Beijing, Chinano status→Not yet recruiting
    • Beijing Xiaotangshan Hospital · Beijing, Chinano status→Not yet recruiting
    • Beijing Zhongguancun Hospital · Beijing, Chinano status→Not yet recruiting
    • Community Health Station of the Party School of the Central Committee of C.P.C · Beijing, Chinano status→Not yet recruiting
    • Jimenli Community Health Service Center · Beijing, Chinano status→Not yet recruiting
    • Peking University First Hospital · Beijing, Chinano status→Not yet recruiting
    • Peking University People's Hospital · Beijing, Chinano status→Not yet recruiting
    • Peking University Third Hospital · Beijing, Chinano status→Recruiting
    • Xueyuanlu Community Health Service Center · Beijing, Chinano status→Not yet recruiting
    • Shanghai East Hospital · Shanghai, Chinano status→Not yet recruiting
    • Wuhan Asia Heart Hospital · Wuhan, Chinano status→Not yet recruiting
    Show site
    • Qingdao Municipal Hospital · Qingdao, China
    Start date Jul 2026→Aug 10, 2026 (now actual)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Beijing Hospital · Beijing, ChinaContact person changed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07693049
Collaborators
Beijing Municipal Health Commission, National Health Commission of the People's Republic of China
Responsible party
Tang Yida (Professor, Vice President of Peking University Third Hospital; Director of Institute of Vascular Medicine, Peking University Third Hospital; Deputy Director, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University Third Hospital) — Principal investigator
First posted
Jul 9, 2026
Start date
Aug 10, 2026
Primary completion
Jul 2027 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Yida Tang, MD,PhD
Contact
tangyida@bjmu.edu.cn
010-82265996
Yida Tang, MD,PhD
study chair · Peking University Third Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion